Takeda Pharmaceutical Co (TAK) last issued guidance on January 29, 2026 for fiscal year 2025. The company guided earnings per share in the range of $3.16 - $3.16, compared to a consensus EPS estimate of . Takeda Pharmaceutical Co also guided revenue in the range of $29.41B - $29.41B for the period.

Compared to prior guidance, Takeda Pharmaceutical Co lowered its EPS outlook from a previous range of $3.25 - $3.25. On the revenue side, the company lowered its revenue forecast from a prior range of $30.52B - $30.52B.

Takeda Pharmaceutical Co has issued 16 guidance updates between May 11, 2022 and January 29, 2026. During this period, the company raised its outlook 8 times and lowered it 7 times, providing investors with insight into management's evolving expectations.